Anti-idiotypic Patents (Class 424/131.1)
-
Publication number: 20120294849Abstract: The present invention provides a method of treating or inhibiting at least one of allergic asthma, allergic rhinitis and atopic dermatitis, or of reducing, inhibiting or treating allergy like symptoms. The methods use compositions comprising chlorite, chloride, chlorate and/or sulfate ions.Type: ApplicationFiled: July 27, 2012Publication date: November 22, 2012Inventors: Mathias Brosz, FRIEDRICH WILHELM KUHNE, KLAUS BLASZKIEWITZ, THOMAS ISENSEE
-
Publication number: 20120282223Abstract: The invention relates to a stable amorphous form of (5-Fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid and its use in the treatment of conditions mediated by the action of PGD2 at the CRTH2 receptor.Type: ApplicationFiled: March 7, 2012Publication date: November 8, 2012Inventors: Aimesther BETANCOURT, Marc LEMIEUX, Roch THIBERT
-
Publication number: 20120266260Abstract: Provided are methods of diagnosing IgA nephropathy in a subject. Optionally, the methods comprise isolating an IgG from the subject and determining whether the IgG binds to a galactose-deficient IgA1. Optionally, the methods comprise providing a biological sample from the subject and detecting in the sample a mutation in a IGH gene, wherein the mutation is in a nucleotide sequence encoding a complementarity determining region 3 (CDR3) of a IGH variable region. Optionally, the methods comprise determining a level of IgG specific for a galactose-deficient IgA1 in the subject. Also provided are methods of treating or reducing the risk of developing IgA nephropathy in a subject.Type: ApplicationFiled: May 26, 2010Publication date: October 18, 2012Inventors: Hitoshi Suzuki, Run Fan, Bruce A. Julian, Jan Novak, Zina Moldoveanu, Zhixin Zhang, Milan Tomana, Jiri Mestecky, Robert J. Wyatt, Yasuhiko Tomino, Yusuke Suzuki, Stephen Olson
-
Publication number: 20120230979Abstract: The invention provides Sp35 polypeptides and fusion proteins thereof, Sp35 antibodies and antigen-binding fragments thereof and nucleic acids encoding the same. The invention also provides compositions comprising, and methods for making and using, such Sp35 antibodies, antigen-binding fragments thereof, Sp35 polypeptides and fusion proteins thereof.Type: ApplicationFiled: March 7, 2012Publication date: September 13, 2012Applicant: Biogen Idec MA Inc.Inventors: Sha MI, John McCoy, R. Blake Pepinsky, Daniel H.S. Lee
-
Publication number: 20120207746Abstract: The invention pertains to the generation and utility of antibodies that can bind effectively to C?mX domain on membrane-bound IgE (mIgE) expressed on the surface of human B lymphocytes. The C?mX domain of 52 amino acid residues, located between the CH4 domain and the C-terminal membrane-anchor peptide on human membrane-bound epsilon chain, had been suggested as an antigenic site for immunological targeting of B cells expressing mIgE. Previous reported monoclonal antibodies, including a20, which bind to RADWPGPP peptide at the C-terminal of C?mX, have now been found to bind poorly to mIgE on human B cells. We have discovered that only monoclonal antibodies specific for certain segments, such as GLAGGSAQSQRAPDRVL and HSGQQQGLPRAAGGSVPHPR, of C?mX can bind effectively to mIgE on human B cells and hence have the utility for targeting those B cells for the treatment of diseases mediated by IgE.Type: ApplicationFiled: February 25, 2010Publication date: August 16, 2012Applicant: ACADEMIA SINICAInventors: Tsewen Chang, Jiun-bo Chen, Pheidias C. Wu, Alfur F. Hung
-
Patent number: 8226947Abstract: The methods and compositions provided herein relate generally to IL-10 specific antibodies and uses thereof. More specifically, compositions of humanized IL-10 specific antibodies and methods to use such antibodies in modulating the biological activity of IL-10, particularly in autoimmune disorders and pathogen-mediated immunopathology.Type: GrantFiled: February 5, 2010Date of Patent: July 24, 2012Assignee: Schering CorporationInventor: Leonard G. Presta
-
Publication number: 20120177635Abstract: The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders.Type: ApplicationFiled: October 25, 2011Publication date: July 12, 2012Applicant: GENENTECH, INC.Inventors: LAWREN WU, MERCEDESZ BALAZS, HANS BRIGHTBILL, ANDY CHAN, YVONNE CHEN, ANAN CHUNTHARAPAL, MARK DENNIS, TERENCE WONG
-
Publication number: 20120177636Abstract: The effective epitope of CA215, a known cancer marker and antigen, has been demonstrated to include a carbohydrate moiety of defined composition and to be non-reactive with anti-human IgG, IgA and IgM, although CA215 is an immunoglobulin heavy chain-like molecule. The defined epitope may be used to prepare immunogenic compositions for treatment and prevention of cancers in humans and may be optimized as to protocol and formulation in animal model systems. Improved protocols for diagnosis and treatment are also described.Type: ApplicationFiled: March 22, 2012Publication date: July 12, 2012Applicant: VANCOUVER BIOTECH LTD.Inventor: Chi-Yu Gregory LEE
-
Publication number: 20120156194Abstract: Methods of diagnosing and treating disorders related to TH2 inhibition, including but not limited to asthma, are provided. Also provided are methods of selecting or identifying patients for treatment with certain therapeutic agents that are TH2 pathway inhibitors.Type: ApplicationFiled: December 16, 2011Publication date: June 21, 2012Applicant: Genentech, Inc.Inventors: Joseph R. Arron, Richard W. Erickson, Michelle Freemer, Meredith Hazen, Guiquan Jia, John G. Matthews, Wendy Putnam, Heleen Scheerens, Yanan Zheng
-
Publication number: 20120148571Abstract: The present invention relates to amino acid sequences that bind to serum proteins such as serum albumin essentially independently in the pH range of 5 to 8; to compounds, proteins and polypeptides comprising or essentially consisting of such amino acid sequences; to nucleic acids that encode such amino acid sequences, proteins or polypeptides; to compositions, and in particular pharmaceutical compositions, that comprise such amino acid sequences, proteins and polypeptides; and to uses of such amino acid sequences, proteins and polypeptides.Type: ApplicationFiled: July 18, 2011Publication date: June 14, 2012Applicant: Ablynx N.V.Inventors: Ignace Joseph Isabella Lasters, Hendricus Renerus Jacobus Mattheus Hoogenboom
-
Publication number: 20120141463Abstract: The present invention relates to the discovery of antibodies that bind to novel epitopes present on membrane-anchored immunoglobulins and which bind to these novel epitopes on the surface of B cells and plasma cells. In addition, the antibodies of the present invention can mediate ADCC and can be useful to deplete those B cells and plasma cells expressing the novel epitopes of the invention. The antibodies of the present invention can be useful for the treatment of B cell-mediated diseases and diseases caused by monoclonal expansion of B cells. Accordingly the present invention also provides compositions and methods for the prevention, management, treatment or amelioration of B cell-mediated diseases and diseases caused by monoclonal expansion of B cells.Type: ApplicationFiled: February 13, 2012Publication date: June 7, 2012Applicant: MedImmune, LLCInventors: Herren Wu, Peter Kiener, Partha S. Chowdhury, James F. Young
-
Publication number: 20120141462Abstract: This invention provides an anti-idiotype antibody that binds to the antigen-binding region of an antibody encoded by antibody genes selected from the group consisting of Set I, Set II, Set III, Set IV, Set V, Set VIa, Set VIb, Set VIc, Set VId, Set VIe, Set VII, and Set VIII, hybridomas and methods of treatments using such.Type: ApplicationFiled: January 20, 2012Publication date: June 7, 2012Inventors: Bradley T. Messmer, Nicholas Chiorazzi, Emilia Albesiano
-
Publication number: 20120134985Abstract: The role of AMPK in arcadian rhythms and methods of screening for agents that modulate such rhythms are disclosed. Compositions that are useful for modulating such rhythms and uses thereof are also disclosed.Type: ApplicationFiled: March 22, 2010Publication date: May 31, 2012Applicant: The Salk Institute for Biological StudiesInventors: Ronald Evans, Katja A. Lamia, Reuben J. Shaw
-
Publication number: 20120114745Abstract: A method for treating or ameliorating mucocutaneous, ocular toxicities, or side effects induced by blocking cellular growth and survival signal transduction pathways. The method comprises administering to a subject in need thereof an effective amount of a histone deacetylase inhibitor and a pharmaceutically acceptable carrier, salt or solvate thereof, wherein the cell growth and survival signal transduction pathways are blocked by an antibody targeted therapy agent, antibody fragment, targeted small-molecule chemical compound, low-molecular-weight tyrosine kinase inhibitor, peptide mimetic, anti-sense oligonucleotide (DNA and/or RNA), or ribozyme.Type: ApplicationFiled: June 26, 2009Publication date: May 10, 2012Inventors: Nam-Mew Pui, Yih-Lin Chung
-
Publication number: 20120100130Abstract: A hetero-dimeric or hetero-oligomeric receptor, comprising at least one chemokine receptor subunit associated with at least one angiotensin receptor subunit.Type: ApplicationFiled: March 26, 2010Publication date: April 26, 2012Applicant: DIMERIX BIOSCIENCE PTY LTD.Inventors: Kevin Donald George Pfleger, Matthew Blake Dalrymple, James Williams, Elizabeth McCall
-
Publication number: 20120100131Abstract: Disclosed is a therapeutic method comprising administering a TIM-3 antibody to a subject who is suspected to be suffering from blood tumor and in whom TIM-3 has been expressed in a Lin(?)CD34(+)CD38(?) cell fraction of bone marrow or peripheral blood or a subject who has been received any treatment for blood tumor. Also disclosed is a composition for preventing or treating blood tumor, which comprises a TIM-3 antibody as an active ingredient. Conceived diseases include those diseases which can be treated through the binding or targeting of the TIM-3 antibody to blood tumor cells (AML cells, CML cells, MDS cells, ALL cells, CLL cells, multiple myeloma cells, etc.), helper T cell (e.g., Th1 cells, Th17 cells), and antigen-presenting cells (e.g., dendritic cells, monocytes, macrophages, and cells resembling to the aforementioned cells (hepatic stellate cells, osteoclasts, microglial cells, intraepidermal macrophages, dust cells (alveolar macrophages), etc)), all of which are capable of expressing TIM-3.Type: ApplicationFiled: April 9, 2010Publication date: April 26, 2012Applicants: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORP., KYOWA HAKKO KIRIN CO., LTDInventors: Shinichiro Takayanagi, Yoshimasa Inagaki, Koichi Akashi, Yoshikane Kikushige
-
Publication number: 20120082661Abstract: This invention provides antibodies that recognize the B Cell Maturation Antigen (BCMA) and that bind naïve B cells, plasma cells, and/or memory B cells. The invention further provides methods for depleting naïve B cells, plasma cells, and memory B cells, and for treating B cell-related disorders, including lymphomas and autoimmune diseases.Type: ApplicationFiled: March 10, 2010Publication date: April 5, 2012Inventors: Susan L. Kalled, Yen-Ming Hsu
-
Publication number: 20120076774Abstract: The present invention provides a method for detecting autoantibodies to osteoprotegerin (OPG). The method comprises the step of providing a biological sample from a subject with, or at risk of osteoporosis and detecting whether or not any antibodies against osteoprotegerin (OPG) are present in said sample. In addition the invention provides methods useful in aiding the diagnosis/prognosis and/or therapeutic regimen for autoimmune and/or vascular disease in general.Type: ApplicationFiled: April 7, 2010Publication date: March 29, 2012Inventors: Philip L. Riches, Stuart H. Ralston, William D. Fraser
-
Patent number: 8133486Abstract: The present invention provides a method for altering a B cell mediated pathology in a patient. This method comprises administering a composition comprising at least one and/or two chimeric proteins. Each chimeric protein comprises at least a portion of either the VH or VL region of a immunoglobulin molecule from particular B cells from a patient having a B cell mediated pathology, and an immunoglobulin constant region. The genes encoding VH and/or VL regions and the genes encoding immunoglobulin constant regions are isolated and inserted into an expression vector. The chimeric proteins are produced by introducing the expression vectors into insect cell lines. The chimeric proteins are purified using antibody affinity columns, and then chemically conjugated to an immunogenic carrier, keyhole-limpet hemocyanin (KLH).Type: GrantFiled: May 10, 2004Date of Patent: March 13, 2012Assignee: MMRGLOBAL, Inc.Inventors: Daniel P. Gold, Robert J. Shopes
-
Publication number: 20120058108Abstract: The present invention relates to the fields of genetics and oncology and provides methods for detecting tumors as well as methods for treating patients and predicting the prognosis to a patient. Specifically, the present invention relates to a method of demonstrating the malignant character of a tumor or cell subpopulation in a subject, to a method of predicting a prognosis, to a method of treating a subject having a tumor with NAV3 copy number change and with over expression of at least one gene or gene product selected from specific lists, and to a method of selecting a treatment to a subject. The present invention also relates to uses of NAV3 gene or gene product and at least one gene and/or gene product selected from specific lists for demonstrating the malignant character of a tumor or cell sub-population, for predicting a prognosis to a subject, for selecting a treatment to a subject, and for cancer therapy in a subject having a tumor with NAV3 copy number change.Type: ApplicationFiled: October 19, 2009Publication date: March 8, 2012Inventors: Kai Krohn, Annamari Ranki, Emilia Carlsson, Kristian Ovaska, Valtteri Häyry, Sampsa Hautaniemi
-
Publication number: 20120052059Abstract: Isolated regulatory B cells are disclosed, and compositions including these isolated regulatory B cells. The isolated regulatory B cells are mammalian and express T cell immunoglobulin mucin-1 (TIM-1). In some embodiments the regulatory B cells produce IL-10. Methods for treating a subject with an immune-mediated disorder are disclosed. These methods include administering to the subject a therapeutically effective amount of a composition including regulatory B cells, thereby treating the immune mediated disorder in the subject. Methods are also disclosed for treating a subject with an immune-mediated disorder, wherein the methods include administering to the subject a therapeutically effective amount of an antibody that specifically binds TIM-1, wherein the antibody is activates TIM-1+CD19+ B cells. Methods are also disclosed for assessing the immune status of a subject.Type: ApplicationFiled: August 31, 2011Publication date: March 1, 2012Inventors: David Rothstein, Qing Ding
-
Patent number: 8110190Abstract: The present invention is related to a monoclonal anti-idiotypic antibody directed against a Factor VIII inhibitor antibody binding to the C1 domain of Factor VIII, as well as to a cell line producing this monoclonal anti-idiotypic antibody, to the use of this monoclonal anti-idiotypic antibody as medicament, and more particularly to the use thereof for manufacturing a medicament intended for the treatment of haemophilia A.Type: GrantFiled: August 23, 2007Date of Patent: February 7, 2012Inventors: Jean-Guy Gilles, Marc G. Jacquemin, Jean-Marie Saint-Remy, Christian Behrens
-
Publication number: 20120020955Abstract: The present invention relates generally to the field of methods of diagnosing a neurological disorder with immune reaction in a mammal. Also disclosed are methods of treating and/or preventing a neurological disorder with immune reaction in a patient.Type: ApplicationFiled: June 24, 2011Publication date: January 26, 2012Inventors: Mehdi Tafti, Michel Muhlethaler
-
Publication number: 20120014940Abstract: The invention relates, at least in part, to the identification of paratarg as a paraprotein target in various malignant and non-malignant gammopathies, which can be used in the diagnosis and treatment of either.Type: ApplicationFiled: January 22, 2010Publication date: January 19, 2012Applicant: Ludwig Institute for Cancer Research Ltd.Inventors: Klaus-Dieter Preuss, Michael Pfreundschuh
-
Patent number: 8092800Abstract: This invention relates to domain antibodies. In particular, it relates to domain antibodies (dAbs) that recognize virulence traits of Candida spp. and confer passive protection against candidiasis.Type: GrantFiled: March 10, 2006Date of Patent: January 10, 2012Assignee: Istituto Superiore di SanitaInventors: Antonio Cassone, Flavia de Bernardis, Steven Grant, Haiqun Liu
-
Patent number: 8080245Abstract: Chimeric molecules that include a pathogen recognition module derived from a pathogen binding domain of a pathogen recognition protein, e.g., a toll-like receptor (TLR), CD14, BPI, MD-2, scavenger receptors (SRs), surfactant proteins (SP), C-reactive protein (CRP), Mannan-binding lectin (MBL), or complement Clq globular binding domain, an optional linker, and an Fc portion of an antibody are described and are useful for, e.g., drug discovery and treatment of conditions related to TLR signaling.Type: GrantFiled: August 4, 2005Date of Patent: December 20, 2011Assignee: University of MassachusettsInventors: Alberto Visintin, Douglas T. Golenbock
-
Patent number: 8080241Abstract: Methods for treating cell proliferative disorders by administering virus to proliferating cells having an activated Ras-pathway are disclosed. The virus is administered so that it ultimately directly contacts proliferating cells having an activated Ras-pathway. Proliferative disorders include but are not limited to neoplasms. The virus is selected from modified adenovirus, modified HSV, modified vaccinia virus and modified parapoxvirus orf virus. Also disclosed are methods for treating cell proliferative disorders by further administering an immunosuppressive agent.Type: GrantFiled: April 16, 2010Date of Patent: December 20, 2011Assignee: Oncolytics Biotech Inc.Inventors: Matthew C. Coffey, Bradley G. Thompson
-
Publication number: 20110300129Abstract: Pharmaceutical compositions of the invention include an antigen or a nucleic acid molecule encoding the antigen; one or both of a PPAR ligand and an RxR ligand; and a pharmaceutically suitable carrier. The pharmaceutical composition can optionally include a mitogen or other additives. Also disclosed are methods of inducing B cell differentiation and promoting an immune response against an antigen.Type: ApplicationFiled: December 14, 2009Publication date: December 8, 2011Applicant: UNIVERSITY OF ROCHESTERInventors: Richard P. Phipps, Tatiana Margarita Garcia-Bates
-
Patent number: 8071094Abstract: The present invention is related to a monoclonal anti-idiotypic antibody directed against a Factor VIII inhibitor antibody binding to the domain A2 of Factor VIII, and to a cell line producing this monoclonal anti-idiotypic antibody, to the use of this monoclonal anti-idiotypic antibody as drug, and more particularly, to its use for the manufacturing of a drug to be used for the treatment of haemophilia A.Type: GrantFiled: July 18, 2006Date of Patent: December 6, 2011Assignee: Laboratoire Francais du Fractionement Et des BiotechnologiesInventors: Christian Behrens, Marc Jacquemin, Jean Guy Gilles, Jean-Marie Saint-Remy
-
Publication number: 20110286963Abstract: The present invention relates to compositions and methods for modulating angiogenesis in vivo, ex vivo or in vitro. More particularly, the invention relates to a soluble CD 146 protein usable in the context of human therapy, as well as to corresponding antibodies. Particular forms of CD 146, herein described, may be used to mobilize, in vivo or ex vivo, both mature and immature endothelial cells, as well as to increase their influence on angiogenesis. The invention also relates to compositions comprising such compounds, particularly pharmaceutical or diagnostic compositions, including kits and the like, as well as methods of therapy or diagnosis using said compounds, compositions and cells.Type: ApplicationFiled: January 29, 2010Publication date: November 24, 2011Applicants: Institut National De La Sante Et De La Recherche Medicale (Inserm), Universite De La MediterraneeInventors: Marcel Blot-Chabaud, Karim Harhouri, Nathalie Bardin, Benjamin Guillet, Françoise Dignat-George
-
Publication number: 20110274651Abstract: Compositions and methods for treating or preventing infectious diseases, and inhibiting the ability of microbes to travel within mammalian cells, and inhibiting microbial replication, are disclosed. The compositions include various noscapine analogs, which are capable of blocking the movement of viruses and other microbes within mammalian and other cells by inhibiting the cytoplasmic transport mechanisms within the cells. The compositions described herein include an effective amount of the noscapine analogues described herein, along with a pharmaceutically acceptable carrier or excipient. The compositions can also include one or more additional antimicrobial compounds.Type: ApplicationFiled: September 4, 2009Publication date: November 10, 2011Applicant: Emory UniversityInventors: Cory Acuff, Daniel Kalman
-
Publication number: 20110274684Abstract: The invention relates to an anti-idiotypical antibody targeting an antibody inhibiting the human fact VIII, said inhibiting antibody targeting the C2 region of the human factor VIII, the variable region of each of the light chains thereof being encoded by a sequence of nucleic acids of which at least 70% is identical to the murine sequence of nucleic acids SEQ ID NO: 1, and the variable region of each of the heavy chains thereof being encoded by a sequence of nucleic acids of which at least 70% is identical to the murine sequence of nucleic acids SEQ ID NO: 2, the constant regions of the light chains and the heavy chains being constant regions from a non-murine species. The invention also relates to the use of said antibody for activating the Fc?RIII receptors of cytotoxic immune cells, and to the production of a medicament especially for the treatment of haemophilia A.Type: ApplicationFiled: May 10, 2011Publication date: November 10, 2011Applicant: LFB BIOTECHNOLOGIESInventors: Christian BEHRENS, Christine Gaucher, Christophe De Romeuf
-
Publication number: 20110268725Abstract: The present invention relates generally to methods of using anti-NGF antibodies in the treatment of various NGF-related disorders, including asthma, arthritis and psoriasis. The methods are effective in treating these disorder in a patient without having a significant adverse effect on the immune system of the patient.Type: ApplicationFiled: April 19, 2011Publication date: November 3, 2011Inventor: David L. Shelton
-
Publication number: 20110256123Abstract: The present invention relates to methods for the modulation of immune responses. More particularly, the invention relates to methods and uses of leptin for immune-modulation of the balance between the Th1/Th2 responses and for the treatment of immune-related disorders. Specifically, the methods of the invention comprise shifting the Th1/Th2 cell balance towards the proinflammatory state. This modulation of the cell balance may be performed by increasing the activity and/or the expression of leptin in a subject, for instance by raising the amount of leptin. The amount of leptin in a subject may be increased by activating immunoregulatory cells, or by administering an immunomodulatory amount of leptin or a homologue, derivative, or functional fragment of leptin.Type: ApplicationFiled: September 7, 2010Publication date: October 20, 2011Inventors: Yaron Ilan, Eran Elinav
-
Patent number: 8038993Abstract: The invention relates to an anti-idiotypical antibody targeting an antibody inhibiting the human factor VIII, said inhibiting antibody targeting the C2 region of the human factor VIII, the variable region of each of the light chains thereof being encoded by a sequence of nucleic acids of which at least 70% is identical to the murine sequence of nucleic acids SEQ ID NO: 1, and the variable region of each of the heavy chains thereof being encoded by a sequence of nucleic acids of which at least 70% is identical to the murine sequence of nucleic acids SEQ ID NO: 2, the constant regions of the light chains and the heavy chains being constant regions from a non-murine species. The invention also relates to the use of said antibody for activating the Fc?RIII receptors of cytotoxic immune cells, and to the production of a medicament especially for the treatment of haemophilia A.Type: GrantFiled: November 2, 2006Date of Patent: October 18, 2011Assignee: LFB BiotechnologiesInventors: Christian Behrens, Christine Gaucher, Christophe De Romeuf
-
Publication number: 20110250171Abstract: The invention relates to immunotherapeutic compounds and to methods for stimulating an immune response in a subject individual at risk for developing cancer, diagnosed with a cancer, in treatment for cancer, or in post-therapy recovery from cancer or the compounds of the invention can be administered as a prophylactic to a subject individual to prevent or delay the development of cancer.Type: ApplicationFiled: June 13, 2011Publication date: October 13, 2011Applicant: Eisai R&D Management Co., Ltd.Inventors: Daniel P. Rossignol, Sally T. Ishizaka, Lynn D. Hawkins, Scott Z. Fields
-
Patent number: 8034338Abstract: The invention refers to an immunogenic recombinant antibody designed for immunization of primates comprising at least a part of a murine IgG2a subtype amino acid sequence and a mammalian glycosylation.Type: GrantFiled: April 16, 2004Date of Patent: October 11, 2011Assignee: Igeneon Krebs-Immuntherapie Forschungs-Und Entwicklungs-AGInventors: Hans Loibner, Gottfried Himmler, Günter Waxenecker, Manfred Schuster, Thomas Putz
-
Publication number: 20110243924Abstract: The invention provides methods of inhalation treatment of a respiratory disease or condition in a patient in need to such treatment without producing in said patient systemic antimuscarinic effects, comprising administering to said patient an effective amount of aclidinium.Type: ApplicationFiled: January 31, 2008Publication date: October 6, 2011Inventor: Jorge Beleta Supervia
-
Publication number: 20110236373Abstract: The present invention relates, in general, to HIV and, in particular to a method of detecting anti-HIV antibodies and antibody-HIV virion complexes.Type: ApplicationFiled: September 24, 2009Publication date: September 29, 2011Inventors: Georgia Tomaras, Barton F. Haynes, Liu Pinghuang, Nicole Yates, Kwan-Ki Hwang
-
Publication number: 20110217291Abstract: Disclosed are soluble hybrid Fc? receptor (Fc?R) polypeptide compositions and related methods of using such polypeptides to treat IgG-mediated and immune complex-mediated inflammation. Also disclosed are related compositions and methods for producing the soluble hybrid Fc?R polypeptides.Type: ApplicationFiled: June 29, 2009Publication date: September 8, 2011Inventors: Carl W. Birks, Brian A. Fox, Mark W. Rixon, Jeff L. Ellsworth
-
Publication number: 20110212084Abstract: This invention relates to binding members, especially antibody molecules, for IgE. The binding members are useful for, inter alia, treatment of disorders mediated by IgE including allergies and asthma.Type: ApplicationFiled: February 15, 2008Publication date: September 1, 2011Applicants: ASTRAZENECA AB, MEDIMMUNE LIMITEDInventors: Duncan Cochrane, Suzanne Cohen, Louise Claire Dobson, Fredick Per-Olof Eriksson, David Phillip Monk, Karin Von-Wachenfeldt
-
Publication number: 20110212161Abstract: Disclosed are a composition and a method for treating skin disorders, including rosacea, pityriasis rosea, erythema, rhinophyma, and rosacea-associated disorders including pimples, papules, pustules, and telangiectasia.Type: ApplicationFiled: February 4, 2011Publication date: September 1, 2011Applicant: Asan Laboratories Company (Cayman), LimitedInventors: Yih-Lin Chung, Nam-Mew Pui, Wei-Wei Chang
-
Publication number: 20110212085Abstract: The present invention provides a method for diagnosing and detecting diseases associated with lung. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in lung diseases (LCAT) and antibodies binds to LCATs. The present invention provides that LCATs are used as targets for screening agents that modulates the LCAT activities. Further the present invention provides methods for treating diseases associated with lung.Type: ApplicationFiled: August 19, 2010Publication date: September 1, 2011Applicant: CELERA CORPORATIONInventors: Elizabeth JOSELOFF, Aiqun LI, Tao HE, Steve RUBEN
-
Patent number: 8010298Abstract: Method, system and an article of manufacture for clustering and thereby identifying predefined antigens reactive with undetermined immunoglobulins of sera derived from patient subjects in need of diagnosis of disease or monitoring of treatment.Type: GrantFiled: January 22, 2009Date of Patent: August 30, 2011Assignee: Yeda Research And Development Co. Ltd.Inventors: Irun R. Cohen, Eytan Domany, Francisco Javier Quintana, Guy Hed, Gad Getz
-
Publication number: 20110195062Abstract: Nucleic acids encoding mammalian, e.g., primate, IL-?, purified IL-1? polypeptides and fragments thereof. Binding proteins, e.g., antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided.Type: ApplicationFiled: April 18, 2011Publication date: August 11, 2011Applicant: Schering CorporationInventor: Jacqueline C. Timans
-
Publication number: 20110189166Abstract: Methods of treating hemorheologic abnormalities in mammals are provided, as well as methods of evaluating circulatory flow mechanics by analyzing hemorheologic determinants or hemorheologic abnormalities in the blood.Type: ApplicationFiled: January 29, 2011Publication date: August 4, 2011Inventor: John BOUCHER
-
Publication number: 20110158981Abstract: The invention provides methods and compositions for inhibiting binding of IgE to a high affinity receptor. The methods and compositions are useful in the treatment of allergic diseases and allergy symptoms in mammals.Type: ApplicationFiled: March 7, 2011Publication date: June 30, 2011Inventors: Eugene Regis Krah, III, Robert Lawton
-
Patent number: 7964186Abstract: Methods for treating cell proliferative disorders by administering virus to proliferating cells having an activated Ras-pathway are disclosed. The virus is administered so that it ultimately directly contacts proliferating cells having an activated Ras-pathway. Proliferative disorders include but are not limited to neoplasms. The virus is selected from modified adenovirus, modified HSV, modified vaccinia virus and modified parapoxvirus orf virus. Also disclosed are methods for treating cell proliferative disorders by further administering an immunosuppressive agent.Type: GrantFiled: May 30, 2007Date of Patent: June 21, 2011Assignee: Oncolytics Biotech Inc.Inventors: Matthew C. Coffey, Bradley G. Thompson
-
Publication number: 20110135633Abstract: The preparation and characterization of antibodies that bind to antigens on CLL or other cancer cells, especially to antigens upregulated in the cancer cells, and the identification and characterization of antigens present on or upregulated by cancer cells are useful in studying and treating cancer.Type: ApplicationFiled: February 16, 2011Publication date: June 9, 2011Applicant: Alexion Pharmaceuticals, Inc.Inventors: Katherine S. Bowdish, John McWhirter
-
Publication number: 20110131669Abstract: Disclosed are compositions and methods for treating Guillain-Barré syndrome (GBS) in a subject that involves neutralizing specific pathogenic anti-glycolipid antibodies in the circulation of the subject. This can involve administering to the subject a molecular mimic of a ganglioside that serves as a specific competitive inhibitor for anti-ganglioside antibodies in the circulation. Also disclosed is an animal model of GBS having anti-ganglioside antibodies in the circulation.Type: ApplicationFiled: May 27, 2010Publication date: June 2, 2011Inventors: Robert Yu, Seigo Usuki